Opinion: A sloppy report on mifepristone is being used to undermine the FDA \u2014 and the biotech industry
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
For decades, the Food and Drug Administration has partnered with clinicians and industry to deliver evidence-based medical innovations using a gold-standard framework for drug development and oversight. The agency has the authority to review any approved drug, and such reviews are a vital part of ensuring public health. That process has long been grounded in transparent and methodologically sound science.<\/p>\n
Now that approach is under threat. In April, the Ethics and Public Policy Center (EPPC), a conservative think tank<\/a>, released a deeply flawed, politically driven report\u00a0with the inflammatory title \u201cThe Abortion Pill Harms Women.\u201d It\u2019s being used to challenge the FDA\u2019s long-standing approval of mifepristone, one of the FDA\u2019s most studied medications. It\u2019s been safely used by millions<\/a> for more than two decades, with over 25 years of data confirming its safety and efficacy.<\/p>\n